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Abstract
Background:  Beginning with the 2004–05 influenza season, the Advisory Committee on
Immunization Practices (ACIP) strengthened their existing encouragement that children aged 6–23
months receive influenza vaccination by creating a formal recommendation.
Methods: Well-functioning sentinel project immunization information systems (IIS) in Arizona
(AIIS) and Michigan (MIIS) were used to calculate vaccination coverage among children aged 6–23
months during the 2004–05 influenza season. We calculated 2 measures of vaccination coverage:
a) receipt of 1 or more doses of influenza vaccine September 2004-March 2005 and b) receipt of
2 or more doses (ie, fully vaccinated). We compared the dose administration distribution among
children needing 1 and 2 doses and by provider type. Coverage by age and timeliness of vaccine
doses entered into the IIS were also analyzed.
Results: Influenza vaccination coverage levels among children were 30% and 27% in AIIS and MIIS,
respectively, for receipt of 1 or more doses; 13% and 11% of children, respectively, were fully
vaccinated. Peaks in dose administration among children needing 1 and 2 doses were similar. There
were differences in vaccine administration between public and private providers. Coverage was
higher among younger children and over 75% of all influenza vaccine doses were entered into the
IIS within 30 days after receipt of vaccine.
Conclusion: Though almost 1/3 of children received 1 or more doses of vaccine in 2 IIS sentinel
projects during the first season of the new recommendation, emphasis needs to be placed on
increasing the proportion of children fully vaccinated. IIS data can be used for timely monitoring of
vaccination coverage assessments.
Background
Influenza causes significant morbidity among children. In
the United States, rates of influenza infection are highest
among children, and those aged 6–23 months are at sub-
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stantially increased risk for influenza-related hospitaliza-
tions [1]. The increased rates of hospitalizations are
comparable with rates for other groups considered to be
at high risk for influenza-related complications [2].
Beginning in 2002, the Advisory Committee on Immuni-
zation Practices (ACIP) encouraged the vaccination of all
children aged 6–23 months with influenza vaccine. Sub-
sequently, beginning with the 2004–05 influenza season,
ACIP changed the encouragement to a recommendation
that all children aged 6–23 months receive influenza vac-
cine annually [3]. Among previously unvaccinated chil-
dren <9 years, 2 doses administered at least 1 month apart
are needed for satisfactory antibody response.
Traditionally, influenza vaccination coverage assessments
have been conducted using data from large national sur-
veys, such as the National Immunization Survey (NIS)
and the National Health Interview Survey (NHIS).
Although these surveys provide nationally representative
results, they require the use of sophisticated statistical and
survey techniques that are labor and cost intensive [4].
Furthermore, these surveys are limited in providing timely
coverage assessments, which are needed in many situa-
tions (eg, to provide immediate information for vaccine
distribution planning during vaccine shortages and to
estimate population-based vaccine-induced immunity
during outbreaks).
Immunization information systems (IIS) are confidential,
computerized systems that maintain vaccine administra-
tion information and have other complex capabilities (eg,
vaccine management, adverse event reporting, and link-
ages with electronic data sources) [5]. These systems are
useful in programmatic and clinical assessments, includ-
ing coverage estimates [6]. A 2004 survey of IIS activity
among 56 Centers for Disease Control and Prevention
(CDC) grantees indicated that approximately 48% of U.S.
children aged <6 years participated (i.e., had ≥ 2 vaccina-
tions recorded) in IIS and that approximately 76% and
39% of public and private provider vaccination sites,
respectively, had submitted data to an immunization
information system during the last 6 months [5]. As IIS
continue to improve nationally, they will likely be able to
produce coverage estimates for all or small subgroups of
children in a more timely fashion than other surveys.
Moreover, well-developed IIS may eventually serve as the
primary means to measure immunization coverage [4].
However, because IIS vary in their levels of provider and
child participation and technological and operational
capabilities, the use of these systems to monitor the over-
all impact of the CDC Recommended Childhood and
Adolescent Immunization Schedule is limited. In 2004,
the CDC funded state health departments in Arizona and
Michigan to establish sentinel projects that were subsets
of the state IIS to evaluate immunization programs in a
specific population. Each sentinel project area was
required to contain populations of at least 200,000 chil-
dren aged ≤ 18 years in contiguous geographic regions; at
least 50,000 of these children had to be <6 years of age,
and ~95% of these children had to be participants in the
IIS. In addition, sentinel projects were required to have
~95% of vaccine provider sites in the area as participants
in the IIS. The IIS databases were also held to certain spec-
ifications; sentinel project databases had to a) have <5%
of duplicate child records (ie, multiple records for the
same child) and b) routinely collect vaccine manufacturer
and vaccine lot number data. In addition, each site con-
ducts quarterly, semi-annual, and annual monitoring of
their IIS data. Based on these requirements, IIS sentinel
site data in Arizona and Michigan are considered high-
quality because they are population-based, comprehen-
sive, and systematically evaluated.
Because 2004–05 was the first season that influenza vacci-
nation was recommended among children aged 6–23
months, establishing an accurate baseline for the contin-
ued assessment of vaccination coverage in this age group
was essential. During the 2004–05 season, however, an
unexpected shortfall of influenza vaccine supply occurred.
In response to this shortage, CDC recommended that vac-
cine be reserved for persons in certain priority groups,
including children aged 6–23 months [7]. In this study,
we describe influenza vaccination coverage among the
newly recommended group of children aged 6–23
months in the 2 IIS sentinel projects during the 2004–05
influenza season.
Methods
This study is based on data from 2 IIS sentinel projects in
Arizona and Michigan through an agreement between
CDC, the Arizona State Immunization Information Sys-
tem Project, and the Michigan Childhood Immunization
Registry. In 2004, the AIIS sentinel project area included 7
primarily rural counties, with a population of ~61,000
children <6 years of age, of which 96% were IIS partici-
pants. Of the children in the sentinel site area, 50% were
white, 32% were Native American or Alaskan Native, 17%
were Hispanic, and 1% were black or Asian or Pacific
Islander. Almost 20% of all persons included in the AIIS
sentinel project area lived below the poverty level. An esti-
mated 97% of provider sites in the sentinel project area
participated in AIIS; among these, 74% were private pro-
vider sites and 26% were public provider sites.
In 2004, the MIIS sentinel site project area included 76
urban and rural Michigan counties with approximately
400,000 children <6 years of age, of which 93% were IIS
participants. Of the children in the sentinel site area, 85%BMC Pediatrics 2007, 7:28 http://www.biomedcentral.com/1471-2431/7/28
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were white, 9% were black, 1% was Asian, and 5% was
other or unknown. Less than 15% of persons included in
the MIIS sentinel project area lived below the poverty
level. An estimated 92% of providers in the sentinel
project area participated in MIIS; among these, 89% were
private provider sites and 11% were public provider sites.
Two measures of vaccination coverage are reported: a)
receipt of ≥ 1 dose of influenza vaccine September 2004-
March 2005 and b) receipt of ≥ 2 doses (i.e., fully vacci-
nated). Specifically, children were considered fully vacci-
nated if they had a) received no doses of influenza
vaccination before September 1, 2004, but then received
2 doses September 1, 2004-March 31, 2005 or b) received
≥ 1 dose of influenza vaccine before September 1, 2004
and then received ≥ 1 additional dose September 1, 2004-
March 31, 2005. Because children aged <6 months are not
eligible for vaccination and because the recommendation
at the time of the study calls for vaccination of children
aged 6–23 months, analyses for both measures included
only those children who were aged 6–23 months during
the entire span of September 2004-March 2005 [8]. Thus,
all children included in the study were born April 1, 2003-
March 1, 2004 and had the same likelihood of being vac-
cinated during the time frame under study.
To assess possible differences in vaccine dose administra-
tion among children needing 1 and 2 doses in the 2004-
05 season, we compared the dose administration distribu-
tion among children needing 1 dose (ie, children who had
previously received a dose of influenza vaccine) and those
needing 2 doses (ie, children who had never received a
dose of influenza vaccine).
To further evaluate vaccination among children aged 6–
23 months, we assessed influenza vaccination doses
administered by public versus private sector provider sites.
Public sector immunization provider sites included local
health departments; federally qualified health centers
(FQHC); Indian Health Service clinics and tribal clinics;
community/migrant health centers/rural health clinics;
military and other state and federal programs; women,
infant, and children programs; public hospitals; and
school district or school, daycare, and Head Start pro-
grams. Private sector immunization provider sites
included private providers, faculty practices, health main-
tenance organizations, and private hospitals (not serving
as an agent for an FQHC). In addition, vaccination cover-
age of ≥ 1 dose was assessed among children who were in
the following 3 age cohorts as of September 1, 2004: a)
children ~6 to 11 months of age, or the "youngest chil-
dren"; b) children ~12 to 17 months of age, or the "mid-
dle children"; and c) children ~18 to 23 months of age, or
the "oldest children". We also assessed the timeliness of
influenza vaccine doses entered into AIIS and MIIS which
were administered during the study time frame.All chil-
dren aged 6–23 months participating in the IIS were
included in this assessment and each sentinel project used
state-specific procedures to extract data from the IIS and to
ensure accurate vaccination record summary. Arizona
used SQL Plus 8.0 (Oracle Corporation, Redwood City,
CA), while Michigan used SAS for Windows 9.1 (SAS
Institute Inc., Cary, NC, 2002) to create the datasets. The
sentinel projects then sent their datasets to the CDC where
analysis was conducted using Excel version 5.1 (Microsoft
Excel, Redmond, Washington). The protocol was deemed
to be exempt from the CDC institutional review board on
the basis that data collected relate to programmatic evalu-
ation as opposed to research involving human subjects.
Results
From September 2004-March 2005, 10,161 children in
AIIS and 65,578 children in MIIS met the age criteria for
this study. Of the children in AIIS, 30% received ≥ 1 dose
of influenza vaccination and 13% were fully-vaccinated;
of the children in MIIS, 27% received ≥ 1 dose of influ-
enza vaccine and 11% were fully-vaccinated.
During the same time period, 4,774 and 23,779 doses of
influenza vaccine were administered to children aged 6–
23 months in AIIS and MIIS respectively. In both sentinel
projects, almost 70% of doses administered were dose 1
to children needing 2 doses and almost 30% were dose 2
administered to children needing 2 doses. Three percent
and 5% of doses administered in AIIS and MIIS respec-
tively were dose 1 to children needing 1 dose. Less than
1% of doses administered in both projects was dose 2
administered to children needing only 1 dose. Peaks in
dose administration among children needing 1 and 2
doses were similar within project areas, with dose 1 peak-
ing in November among both groups of children in AIIS
and dose 1 peaking in October among both groups of
children in MIIS (Figure 1).
Variability was observed among doses administered in the
public and private sector by state. In AIIS, public provider
sites administered 61% of doses and private provider sites
administered 39% of doses. In MIIS, public provider sites
administered 26% of doses and private provider sites
administered 74% of doses. The administration of all vac-
cine doses was highest for both public and private pro-
vider sites in October in Michigan and in November in
Arizona (Figure 2).
In both sentinel projects, vaccination coverage with ≥ 1
dose was higher among the younger age cohorts. In the
Arizona sentinel project area, vaccination coverage among
children in both the youngest and middle age groups of
children was 31%, and was 24% among the oldest group
of children. In the Michigan sentinel project area, cover-BMC Pediatrics 2007, 7:28 http://www.biomedcentral.com/1471-2431/7/28
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age was 29%, 28%, and 23% among the youngest, mid-
dle, and oldest age groups, respectively.
Of the ~5,000 vaccine doses administered to children
aged 6–23 months in the Arizona sentinel project area,
60% were entered into AIIS within 2 weeks of administra-
tion and over 75% were entered within 30 days. Of the
~24,000 doses administered to children aged 6–23
months in the Michigan sentinel project area, 77% were
entered into MIIS within 2 weeks of administration and
over 85% were entered within 30 days.
Discussion
Fall 2004 marks the first season in which ACIP recom-
mended influenza vaccination of all children aged 6–23
months. Data from the Arizona and Michigan IIS sentinel
projects indicated that almost 1/3 of children in this age
group received ≥ 1 dose of vaccine and approximately 1/
10 of these children were fully vaccinated during the
2004–05 season. Though approximately 30% coverage
with ≥ 1 dose is not unexpected during the first season
after a new recommendation, this coverage level, com-
bined with the low coverage of fully vaccinated children
illustrates that physicians and parents need to be targeted
for educational efforts regarding the new recommenda-
tion. Several recent studies have added to the growing
body of literature regarding the importance of a 2nd dose
of influenza vaccine in providing protection for young
children. These studies have found minimal to no protec-
tion against influenza in young children without the 2nd
dose following the immunologic priming of the 1st dose
[9,10]. Indeed, a recent study indicated that during a year
with suboptimal vaccine match no vaccine effectiveness
was demonstrated in children aged 6–23 months after
only 1 dose [11]. Such evidence regarding the importance
of the 2nd dose prompted ACIP to emphasize receipt of the
booster dose in children in its 2006 influenza recommen-
dations [12]. The vaccine administration distribution
demonstrated in this study reveals that the distribution
among children needing 1 and 2 doses of vaccine was sim-
ilar in each project site. The overwhelming majority of
doses were administered by the end of December, indicat-
Percent of influenza vaccine dose administration among children needing 1 and 2 doses, 2004–2005 season Figure 1
Percent of influenza vaccine dose administration among children needing 1 and 2 doses, 2004–2005 season.BMC Pediatrics 2007, 7:28 http://www.biomedcentral.com/1471-2431/7/28
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ing that children who are receiving vaccine are receiving it
before the typical peak influenza activity in the United
States [13].
Whether and how much the shortage impacted coverage
among children aged 6–23 months remains a question,
difficult to answer during the first year of a recommenda-
tion for vaccination in this group. On the one hand, the
vaccine shortage during the 2004–05 season was due to
loss of vaccine manufactured by Chiron, a vaccine not
licensed for use in children aged 6–23 months; thus, over-
all supplies for children <4 years of age were not affected
and doses of vaccine for children remained unpurchased
on the federal vaccine contracts at the end of the season.
A survey of parents indicated that over 75% of parents
who tried to get the vaccine for their children aged 6–23
months were able to do so [14]. In addition, anecdotal
reports indicated a surplus of the pediatric formulation at
the end of the season in public provider offices that used
vaccine purchased through the federal contract (G. Wal-
lace, CDC, personal communication, February, 2006).
Although the Arizona Department of Health Services
redistributed vaccine in response to the shortfall of doses
from Chiron, we have no information about how this
may have impacted the availability of vaccine for young
children aged 6 – 23 months. Finally, despite the shortage,
100% of vaccine from Aventis Pastuer ordered by private-
sector pediatric offices was shipped. However, it is still
possible that the shortfall of vaccine could have impacted
some children. Providers ordering only the Aventis Pas-
teur formulation, indicated for persons aged 6 months
and older, may have gotten less vaccine than requested or
may have used this product to vaccinate adults whom they
had originally planned to vaccinate with the Chiron prod-
uct, either of which could have decreased the amount of
vaccine available in these practices for use in young chil-
dren.
In both sentinel project areas, higher coverage levels were
observed among the youngest and middle-aged groups of
children compared with the oldest age group. The
younger and middle age groups were within the recom-
mended age range intervals for administration of other
childhood vaccines during the entire study period, while
the older age group was not. Therefore, the older age
group may have had lower coverage because they were less
likely to have a visit scheduled for administration of other
vaccines.
Use of IIS provides a unique opportunity to assess immu-
nization coverage rates. In theory, IIS can provide meas-
ures of vaccination coverage at all population levels [4].
Furthermore, unlike many surveys, IIS allow data to be
collected in a manner which facilitates timely program-
matic analysis and decision-making. The CDC IIS Techni-
cal Working Group established a goal for all IIS that called
for immunization data to be received and processed by IIS
within 30 days of vaccine administration [15]. In both
sentinel project areas, over 75% of the influenza vaccine
doses were entered into the IIS within 30 days after receipt
of vaccine. In addition, the IIS enabled the prompt assess-
ment of coverage for fully vaccinated children, including
those receiving at least one dose of vaccine during the pre-
vious season.
Public and private sector doses of influenza vaccine by sentinel project area, 2004–2005 season Figure 2
Public and private sector doses of influenza vaccine by sentinel project area, 2004–2005 season.BMC Pediatrics 2007, 7:28 http://www.biomedcentral.com/1471-2431/7/28
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The findings of this study are subject to at least 2 impor-
tant limitations. First, though provider site participation
rate in the IIS sentinel sites is high, the completeness of
reporting by participating sites is unknown and there
remain some sites in these areas who do not contribute
their immunization data to the IIS. This lack of reporting
could have resulted in an underestimate of vaccination
coverage in the geographic area under study. Second,
because study results are reported from only 2 sentinel
project areas, they may not be generalizable to the overall
U.S. population. However, the population included in
these 2 project areas represents a demographically diverse
group of individuals.
Other investigations have examined influenza vaccination
coverage among children aged 6–23 months for the
2004–05 influenza season. A study conducted using the
Behavioral Risk Factor Surveillance System (BRFSS),
found coverage of ≥ 1 dose among U.S. children to be
48% September 2004 -January 2005 [16]. Similar to the
current study, children included in the BRFSS study were
aged 6–23 months during the entire season. A study con-
ducted by Kaiser Permanente Northern California using
cumulative coverage estimates September 2004 through
March 2005 among children 6–23 months of age found
receipt of ≥ 1 dose to be 58% [17]. However, comparabil-
ity of these studies with the current study is limited
because the populations under study are different and
generalizability among them is difficult. For example,
although we attempted to compare Arizona and Michigan
state-specific BRFSS results to the results obtained in the
IIS sentinel project study, the BRFSS sample size among
children aged 6–23 months was too low to calculate a
meaningful coverage estimate (Michael Link, CDC, per-
sonal communication, September 2005). In addition,
unlike IIS data, BRFSS data are self-reported and subject to
recall bias, potentially resulting in an overestimate of vac-
cination coverage [16]. Finally, estimates from the Kaiser
study were obtained only from an insured, northern Cali-
fornia population, which is likely demographically differ-
ent from the 2 populations included in our study.
NIS influenza vaccination coverage estimates for the
2003–04 and 2004–05 seasons and the current study's
data show increasing trends in coverage among children
aged 6–23 months, which temporally parallels the
strengthening ACIP vaccination recommendations
[18,19]. Similar to the current study, childhood coverage
assessments in children aged 6–23 months include only
those children who were aged 6–23 months during the
entire span under study. The 2003–04 NIS coverage esti-
mates of ≥ 1 dose of vaccine in Arizona and Michigan were
16% and 17% respectively; and 7% and 8% respectively
for children fully vaccinated. Estimates of 2004–05 NIS
data and IIS data are similar, with NIS coverage of ≥ 1 dose
in Arizona and Michigan at 27% [95% CI 21%, 33%] and
31% [95% CI 24%, 38%] respectively, and coverage of
children fully vaccinated at 12% [95% CI 9%, 17%] and
16% [95% CI 11%, 22%] respectively [19].
Conclusion
The current study indicates that almost 1/3 of children
aged 6–23 months were vaccinated with ≥ 1 dose of influ-
enza vaccination in 2 IIS sentinel project areas during the
first year of the ACIP recommendation; however, full vac-
cination coverage was low. Much work is needed to fully
implement the new recommendation and to increase cov-
erage of the 2nd dose of vaccine, including educating pro-
viders and parents on the importance of receipt of the 2nd
dose. Though effort needs to be placed in increasing pro-
vider site and child participation rates in IIS to help ensure
that all influenza vaccine doses are entered into the IIS,
this study illustrates that data from well-functioning IIS
are useful for measuring vaccination coverage. In addi-
tion, IIS can produce more timely results than some other
methods, which may not yield results until after the cur-
rent influenza season and the data collection phase ends.
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